More than 250 neurological specialists expected to attend conference in Bogotá, Feb. 15
/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S./
TORONTO, Jan. 23, 2018 /CNW/ - Khiron Life Sciences Corp., a Canadian integrated medical cannabis company with its core operations in Colombia, will welcome Colombia's medical community as co-host of the inaugural International Medical Cannabis Symposium taking place Feb. 15 in Bogotá, Colombia. The symposium, which is the first such event to be held in the country, is being co-hosted with the Colombian Association of Neurologists.
Alvaro Torres, President and CEO of Khiron, says, "As Khiron prepares to introduce its first medicinal cannabis products to the Colombian market this year, it is extremely important that physicians and clinicians across the country get access to the latest global research, together with a better understanding of the health applications for medicinal cannabis."
The symposium will feature leading international medical cannabis researchers from Canada, Israel and Latin America, who will provide a detailed introduction to medicinal cannabis applications in clinical practice.
Symposium speakers include:
- Dr. Michael Dor, Chief Medical Officer, Ministry of Foreign Affairs and the Medical Head Advisor of the Medical Cannabis Unit for the Israeli Ministry of Health.
- Dr. Vincent Maida, a consultant in Palliative Medicine and Wound Management at the William Osler Health System in Toronto.
- Dr. Sergio Ramirez, president of the Colombian Association of Neurologists and founder and Head of service at the Laboratory of Neurophysiology at San Rafael University Hospital, Bogotá.
- Dr. Danial Schecter, co-founder of the Cannabinoid Medical Clinic (CMClinic) in Toronto and one of Canada's leading experts in medical cannabis.
A full event schedule and registration details are available at: http://simposiomedicocannabis.com
Dr. Sergio Ramirez, President of the Colombian Association of Neurology, comments, "In line with our mission of ensuring the wellbeing of patients with neurological conditions and to foster constructive and ethical research in Colombia, our association fully endorses the Khiron Symposium on the Medicinal Use of Cannabis, as it will open some much needed discussion on this important public health topic."
Medicinal cannabis documentation procedures, medical advisories and a summary of clinical trials from around the world will be reviewed and discussed at the symposium. In addition, the international regulatory environment for medical cannabis will be reviewed and an overview provided of the new domestic laws and regulations in Colombia, which legalized medical cannabis in 2016.
"There is still a wide gulf of knowledge concerning the administration of prescribed medicinal cannabis around the world," says Dr. Paulo Vega, Medical Director for Khiron, "the full range of alternative canniceutical and phytotherapeutic products needs to be reviewed and discussed. Understandably, physicians here in Colombia and across Latin America want to gain a better understanding and appreciation of the many therapeutic benefits of medicinal cannabis."
The symposium is being organized by Khiron Life Sciences, one of the first firms in Colombia to be fully licensed to grow and cultivate cannabis for medicinal products for domestic distribution and export sale. A key element of Khiron's strategic development strategy is to focus on engaging and educating the medical community in Colombia and across Latin America about the benefits of medicinal cannabis.
About Khiron Life Sciences Corp.
Khiron Life Sciences is a Canadian integrated medical cannabis company with its core operations in Colombia. Khiron combines leading international scientific expertise, agricultural advantages and branded product market entrance experience to address the unmet medical needs in a market of over 620 million people in Latin America. Khiron has received licences in Colombia for high- and low-tetrahydrocannabinol (THC) medical cannabis, and is now in receipt of all licences required for the cultivation, production, domestic distribution, and international export of both THC and cannabidiol (CBD) medical cannabis.
Further information on the Company can be accessed through the link below:
FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, Khiron assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks. This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
SOURCE Khiron Life Sciences Corp.
For further information: On behalf of the Board of Directors: Alvaro Torres, Chief Executive Officer, Direct: +57 (320) 4950326, Email: firstname.lastname@example.org; Darren Collins, Chief Financial Officer, Direct: +1 (705) 527 3564, Email: email@example.com